Payment overview · 2025
General Payments
$1,797.07
78 reported records · 24 companies
Healthcare provider profile · identity verified
Doha Ayish, M.D, M.B.B.S
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HOUSTON, TX · NPI 1891180253
Verified facts
What the public records show
CMS Open Payments records show Doha Ayish, M.D, M.B.B.S received $1,797.07 in general payments during 2025 across 78 reported records.
ABBVIE INC. accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuplazid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $630.53 | 35.1% | 31 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $190.70 | 10.6% | 9 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $91.57 | 5.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $75.86 | 4.2% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$73.58 | 4.1% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $71.11 | 4.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.84 | 3.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.21 | 3.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $52.44 | 2.9% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.00 | 2.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$48.22 | 2.7% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $45.04 | 2.5% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $42.76 | 2.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.51 | 2.2% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $39.18 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.13 | 2.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $34.08 | 1.9% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $29.47 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.59 | 1.3% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $21.09 | 1.2% | 1 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $20.95 | 1.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.50 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.31 | 1.1% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $18.40 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,797.07 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $431.25 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $333.72 | 14 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $190.70 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.49 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $98.45 | 5 | 2025 |
Source payment records
|
|||||
| SENZA Normalized: senza |
Device | Globus Medical, Inc. | $91.57 | 1 | 2025 |
Source payment records
|
|||||
| SI-LOK Normalized: si lok |
Device | Globus Medical, Inc. | $91.57 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $71.11 | 3 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $54.21 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $52.44 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $52.00 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $48.22 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| CODMAN CERTAS Normalized: codman certas |
Device | Integra LifeSciences Corporation | $42.76 | 1 | 2025 |
Source payment records
|
|||||
| CODMAN HAKIM Normalized: codman hakim |
Device | Integra LifeSciences Corporation | $42.76 | 1 | 2025 |
Source payment records
|
|||||
| CUSA CLARITY Normalized: cusa clarity |
Device | Integra LifeSciences Corporation | $42.76 | 1 | 2025 |
Source payment records
|
|||||
| DuraSeal Exact Spinal Sealant System Normalized: duraseal exact spinal sealant system |
Device | Integra LifeSciences Corporation | $42.76 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $34.08 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 230 | 75 |
| Donepezil Hcl | Donepezil Hcl | 102 | 37 |
| Memantine Hcl | Memantine Hcl | 100 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | 25 |
| Sertraline Hcl | Sertraline Hcl | 65 | 18 |
| Pregabalin | Pregabalin | 57 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 32 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | 11 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 15 |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Baclofen | Baclofen | 22 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Solu-Cortef | Hydrocortisone Sodium Succ/Pf | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,797.07 · 78 records | ABBVIE INC. | AUSTEDO XR, BOTOX, CODMAN CERTAS, CODMAN HAKIM, CREXONT, CUSA CLARITY, DUROLANE, DuraSeal Exact Spinal Sealant System, ETERNA, General - DBS, INCEPTIV, INFINITY, INGREZZA, Leqembi, MONOVISC, NUPLAZID, NURTEC ODT, ORTHOVISC, PROCLAIM, QULIPTA, REXULTI, Rystiggo, SENZA, SI-LOK, SPRINT PNS System, Symbravo, UBRELVY, ULTOMIRIS, VYALEV, VYVGART HYTRULO, Xeomin, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error